• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Officer Oien Jessica

    1/23/25 4:05:07 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Oien Jessica

    (Last) (First) (Middle)
    C/O BOUNDLESS BIO, INC.
    10955 ALEXANDRIA WAY, SUITE 100

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Boundless Bio, Inc. [ BOLD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    01/22/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $2.57 01/22/2025 A 90,000 (1) 01/21/2035 Common Stock 90,000 $0 90,000 D
    Explanation of Responses:
    1. The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025.
    Remarks:
    Chief Legal Officer and Corporate Secretary
    /s/ Jessica Oien 01/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BOLD

    DatePrice TargetRatingAnalyst
    6/2/2025$5.00Buy
    H.C. Wainwright
    5/28/2025$3.00Outperform → Market Perform
    Leerink Partners
    12/13/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $BOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Boundless Bio Inc.

      SC 13D - Boundless Bio, Inc. (0001782303) (Subject)

      10/29/24 6:32:08 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boundless Bio Announces Portfolio Prioritization and Runway Extension

      Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates focused on optimizing the Company's portfolio for p

      5/23/25 4:01:00 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

      Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing in the first half of 2026 $138 million cash position provides operating runway into 2027 SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended

      5/9/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio to Participate in the Needham Virtual Healthcare Conference

      SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham's Virtual Healthcare Conference. A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website and can be accessed via this link: https://wsw.com/webcast/needham14

      4/3/25 7:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Financials

    Live finance-specific insights

    See more
    • Boundless Bio Announces Portfolio Prioritization and Runway Extension

      Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates focused on optimizing the Company's portfolio for p

      5/23/25 4:01:00 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

      SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert ("Bob") Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. "We are excited to have Bob join Boundless at this pivotal time as we continue to advance the BBI-355 Phase 1/2 POTENTIATE trial and approach the selection of a development candidate for our Kinesin program," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "Bob has been a driving force behind precisio

      2/3/25 10:00:00 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Doebele Robert

      4 - Boundless Bio, Inc. (0001782303) (Issuer)

      2/3/25 6:38:53 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Doebele Robert

      3 - Boundless Bio, Inc. (0001782303) (Issuer)

      2/3/25 6:29:34 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Hassig Christian

      4 - Boundless Bio, Inc. (0001782303) (Issuer)

      1/23/25 4:05:10 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    SEC Filings

    See more
    • Boundless Bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events

      8-K - Boundless Bio, Inc. (0001782303) (Filer)

      5/23/25 4:06:08 PM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Boundless Bio Inc.

      10-Q - Boundless Bio, Inc. (0001782303) (Filer)

      5/9/25 7:10:19 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Boundless Bio, Inc. (0001782303) (Filer)

      5/9/25 7:05:23 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Boundless Bio with a new price target

      H.C. Wainwright initiated coverage of Boundless Bio with a rating of Buy and set a new price target of $5.00

      6/2/25 8:50:41 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Boundless Bio from Outperform to Market Perform and set a new price target of $3.00

      5/28/25 8:09:07 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Boundless Bio downgraded by Guggenheim

      Guggenheim downgraded Boundless Bio from Buy to Neutral

      12/13/24 7:26:11 AM ET
      $BOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care